Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Consensus Rating of “Moderate Buy” from Analysts

Entrada Therapeutics, Inc. (NASDAQ:TRDA) has been given an average recommendation of “Moderate Buy” by the five ratings firms that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $18.50.

Several research analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (d)” rating on shares of Entrada Therapeutics in a research report on Monday, December 29th. HC Wainwright reissued a “buy” rating and set a $20.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, February 18th. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 11th. Oppenheimer began coverage on shares of Entrada Therapeutics in a report on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 target price on the stock. Finally, Wall Street Zen raised shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th.

Entrada Therapeutics Stock Up 8.3%

NASDAQ:TRDA opened at $12.58 on Friday. The company’s 50 day moving average is $11.05 and its 200-day moving average is $8.69. Entrada Therapeutics has a 12 month low of $4.93 and a 12 month high of $12.93. The firm has a market cap of $481.56 million, a price-to-earnings ratio of -3.64 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative return on equity of 39.83% and a negative net margin of 565.48%. Research analysts predict that Entrada Therapeutics will post 1.12 EPS for the current fiscal year.

Key Entrada Therapeutics News

Here are the key news stories impacting Entrada Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and maintained a $20.00 price target on TRDA, which signals meaningful upside from current levels and likely supported buying interest. HC Wainwright note
• Positive Sentiment: HC Wainwright nudged its Q1 2026 EPS estimate to a smaller loss (from ($1.20) to ($1.12)), a modest improvement that can be read as slightly better near‑term expectations for operating performance. HC Wainwright note
• Neutral Sentiment: Short‑interest data reported a jump claim but shows 0 shares short (short‑interest ratio 0.0 days); this appears to be a data anomaly. If accurate, near‑zero reported short interest reduces downward short‑pressure, but the feed’s inconsistency makes this point uncertain. Short interest report
• Negative Sentiment: HC Wainwright cut several near‑term EPS forecasts (Q2–Q4 2026 and FY2026 lowered; FY2026 moved to ($4.49) from ($4.21)) and trimmed multiple 2026/2027 quarterly EPS views, signaling larger expected losses in the near term. Deteriorating near‑term profitability expectations could pressure the stock if operational or cash‑burn concerns persist. HC Wainwright note

Insider Activity

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 7,988 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $12.25, for a total value of $97,853.00. Following the transaction, the chief financial officer directly owned 137,987 shares in the company, valued at approximately $1,690,340.75. This trade represents a 5.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 8.11% of the company’s stock.

Institutional Investors Weigh In On Entrada Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC boosted its holdings in shares of Entrada Therapeutics by 9.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,495 shares of the company’s stock valued at $176,000 after buying an additional 1,560 shares during the period. Alliancebernstein L.P. lifted its position in Entrada Therapeutics by 7.1% in the 3rd quarter. Alliancebernstein L.P. now owns 24,320 shares of the company’s stock valued at $141,000 after acquiring an additional 1,620 shares in the last quarter. Great Lakes Advisors LLC lifted its position in Entrada Therapeutics by 5.5% in the 4th quarter. Great Lakes Advisors LLC now owns 43,268 shares of the company’s stock valued at $445,000 after acquiring an additional 2,239 shares in the last quarter. Intech Investment Management LLC boosted its position in shares of Entrada Therapeutics by 15.7% during the second quarter. Intech Investment Management LLC now owns 17,702 shares of the company’s stock worth $119,000 after buying an additional 2,397 shares during the period. Finally, Quadrature Capital Ltd grew its holdings in shares of Entrada Therapeutics by 13.5% during the fourth quarter. Quadrature Capital Ltd now owns 20,318 shares of the company’s stock worth $209,000 after buying an additional 2,424 shares in the last quarter. Institutional investors own 86.39% of the company’s stock.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.